Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Aligos Therapeutics Inc. ALGS

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:ALGS)

Fundamentals Snapshot (NDAQ:ALGS)

Current News (NDAQ:ALGS)

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results

GlobeNewswire 6 days ago

Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022

GlobeNewswire July 27, 2022

Aligos Therapeutics Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184

GlobeNewswire July 25, 2022

Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184, First Clinical Data for NASH Drug Candidate ALG-055009 and Nonclinical Data in Other Chronic Hepatitis B Programs at the European Association for the Study of the Liver's Digital International Liver Congress(TM) 2022

GlobeNewswire June 22, 2022

Aligos Therapeutics to Participate in Metropolitan AntiViral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic Potential

GlobeNewswire June 6, 2022

Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference

GlobeNewswire May 23, 2022

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results

GlobeNewswire May 4, 2022

Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver's International Liver Congress(TM) 2022

GlobeNewswire May 3, 2022

Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022

GlobeNewswire April 27, 2022

Opinion & Analysis (NDAQ:ALGS)

No current opinion is available.

Bullboard Posts (NDAQ:ALGS)

5 Things to Know About Aligos Therapeutics!

$ALGS Aligos Therapeutics, Inc. (NASDAQ: ALGS), a clinical-stage biotechnology company, has discontinued development of ALG-020572,...
AviseAnalytics - March 28, 2022